NUVB Nuvation Bio Inc. Insider Trading

Nuvation Bio CPO Markel sells 125,000 shares ($753.2K) via scheduled 10b5-1 plan; retains 32.6K shares plus 629,810 options

Stacy Markel, Chief People Officer at Nuvation Bio, sold 125,000 shares at $6.03 under a pre-arranged 10b5-1 trading plan on 2026-06-23, reducing non-derivative holdings to 32.6K shares from 157.6K shares. The sale totaled $753.2K and reflects execution of a scheduled plan rather than a discretionary decision. Markel's cross-ticker track record shows 1 prior open-market buy with 90d return +91.2%, but this ticker-specific transaction at NUVB has only 1 prior measurable event (a 2025-06-18 buy with similar 90d outcome of +91.2%). The company reported annual revenue growth of +699.0% and posted net income of $5.4M in the latest quarter, though it remained unprofitable over the full fiscal year. The stock has appreciated +36.9% over 30 days and +46.2% over 90 days from the transaction date, and currently trades at $6.46, down 33.7% from its 52-week high of $9.75.

Director Robert Mashal buys 25,000 shares of NUVB at $4.73; all 4 prior same-ticker purchases show 90d gains, currently -51.2% from 52-week high

Director Robert Mashal purchased 25,000 shares at $4.73, increasing his holdings to 225,000 shares (+12.5% increase). His track record at NUVB is notable: all 4 prior open-market purchases at this ticker showed positive 90-day returns (ranging from +16.8% to +29.4%), indicating consistent timing on the buy side. The current price of $4.76 sits -51.2% from the 52-week high of $9.75, meaning the stock has declined substantially from recent peaks. Fundamentally, the company posted $83.2M in revenue and $5.4M net income in its latest quarter, alongside +699.0% annual revenue growth, though it remains unprofitable on a full-year basis, creating a contrast between strong top-line momentum and unresolved profitability concerns.

CMO Liu Dongfang sells 150,000 shares (89.3% of holdings) at $7.82; stock at 52-week high, fundamentals deteriorating

Liu Dongfang, Chief Medical Officer, sold 150,000 shares for $1,173,255.00, reducing his position from 168,000 shares to 18,000 shares—a 89.3% reduction in holdings. The sale occurred at $7.82 while the stock currently trades at $8.37, which is at its 52-week high, having appreciated 61.9% over 30 days and 144.7% over 90 days. Against this backdrop of sharp recent gains, the company remains deeply unprofitable with net income of $-55,792,000.00 against quarterly revenue of $13,120,000.00, indicating the CMO's substantial share reduction took place during a period of elevated valuation relative to deteriorating financial performance. The magnitude of the position reduction—retaining only 18,000 shares—represents a material shift in disclosed insider exposure to the company.

Chief Scientific Officer Gary Hattersley fully exits NUVB position: 369,051 shares sold for $2.7M, reducing holdings to 0

Gary Hattersley, Chief Scientific Officer at Nuvation Bio, executed 2 separate sales totaling 369,051 shares for $2,667,131.58 on 2025-11-20, completely liquidating his holding. The blended sale price of $7.23 occurs just 18 basis points below the current price of $7.41, positioning this exit near recent highs—notably at the 52-week high. The complete exit by a senior scientific executive is noteworthy given the company's financial profile: NUVB posted net income of $-55,792,000.00 against revenue of $13,120,000.00 in the latest quarter, leaving it unprofitable. This full divestment of an officer's entire stake, combined with the company's ongoing cash burn, warrants close attention from investors evaluating management's confidence in the therapeutic pipeline and capital runway.

Chief Technical Operations sold 200,000 shares (89.3% reduction) of NUVB at $7.14; stock up 68.4% in 30 days, company unprofitable.

Hanley David C., Chief Technical Operations at Nuvation Bio, executed a substantial sale of 200,000 shares on 2025-11-19 at $7.14, reducing his holdings from 224,000 shares to 24,000 shares (an 89.3% reduction). This occurs against a backdrop of significant recent price appreciation: the stock has gained 68.4% over the past 30 days and 141.0% over 90 days, now trading at $6.99, just 2.2% below its 52-week high of $7.15. Despite the strong recent momentum, Nuvation Bio remains unprofitable with a net loss of $55,792,000.00 on revenue of $13,120,000.00 in its latest quarter, indicating fundamental challenges persist regardless of near-term share price strength. The magnitude of this insider stake reduction—nearly 9-of-10 shares sold by the CTO—combined with the stock's proximity to 52-week highs while the company sustains significant operating losses, presents a material signal for investor scrutiny of near-term catalysts and management confidence at elevated valuations.

NUVB CEO Hung David bought 500,000 shares at $1.79; stock down 53.3% from 52-week high, cluster buy pattern from 4 other insiders in past 14 days

Hung David, President and CEO, purchased 500,000 shares at $1.79 on 2025-06-16, expanding his position from 58.78M to 59.28M shares. The buy occurs with the stock trading 53.3% below its 52-week high of $3.83 and down 22.2% over the past 30 days, while the company remains unprofitable with a net loss of $53.2M in its most recent full fiscal year. Notably, four other insiders have also purchased shares within the past 14 days, creating a cluster buying pattern. David's own cross-ticker track record shows an average 30-day return of +36.7% on his two prior open-market purchases, though his two prior NUVB-specific buys (2025-04-04 and 2025-04-07) have produced 30-day gains of 47.9% and 25.5% respectively, with longer-term outcomes not yet measurable.

CFO Sauvage Philippe bought 7,300 shares in 2 transactions for $13,215.50; holdings +280.6%. Cluster buy signal with 4 other insiders in past 14 days.

Sauvage Philippe, Chief Financial Officer of Nuvation Bio, purchased 7,300 shares across 2 separate transactions on 2025-06-16 and 2025-06-17 at a blended average price of $1.81, increasing his holdings from 2,602 to 9,902 shares (a +280.6% increase). This filing is part of a cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated interest at current valuation levels despite the company reporting negative net income of $-53,236,000.00 in its most recent period and a market cap of $609,070,727.04. The stock has declined -53.3% from its 52-week high of $3.83 and -22.2% over the past 30 days, meaning these purchases occurred during a period of significant price erosion. This multi-insider buying activity against deteriorating fundamentals and falling price momentum warrants examination into whether management sees near-term catalysts or believes current levels represent structural opportunity.

Nuvation Bio CPO buys 10,000 shares at $1.71 in cluster pattern; stock down -53.3% from 52-week high amid $-53.2M annual loss.

Markel Stacy, Chief People Officer at Nuvation Bio Inc., purchased 10,000 shares at $1.71 on 2025-06-18, increasing holdings by 51.0% to 29,591 shares total. This transaction occurred amid a broader insider buying cluster of 4 other insiders acquiring shares within the past 14 days, while the stock trades 53.3% below its 52-week high of $3.83 and the company carries a full-year net loss of $-53,236,000.00 against quarterly revenue of $3,084,000.00. The combination of coordinated insider accumulation at depressed valuation levels, concurrent with substantial unprofitability, presents a material data point requiring deeper investigation into whether management's simultaneous buying reflects internal conviction or reflects valuations unrelated to underlying fundamentals.

Chief Regulatory Officer Wentworth Kerry purchased 50,000 shares at blended average $1.79 totaling $89,740.00; stock is -53.3% from 52-week high and company is unprofitable with -$53.2M net income.

Wentworth Kerry, Chief Regulatory Officer at Nuvation Bio, executed two separate purchases totaling 50,000 shares for $89,740.00 on 2025-06-16, establishing a position from zero prior holdings. The stock is trading at $1.79, down 53.3% from its 52-week high of $3.83 and down 22.2% over the past 30 days, while the company reported negative net income of $-53.2M on quarterly revenue of $3.1M. The filing occurs within a cluster period in which 4 other insiders also bought within the past 14 days, indicating coordinated insider buying activity during a period of significant stock price deterioration and operational losses. This pattern merits observation given the insider's regulatory function and the concurrent buying momentum from peer executives.

Chief Commercial Officer Colleen Sjogren purchases 50,000 shares of NUVB at $1.81; cluster of 4 other insiders buying within 14 days.

Sjogren purchased 50,000 shares at $1.81 on 2025-06-16, raising her holdings from 31,000 to 81,000 shares (+161.3% vs pre-transaction holdings). This buy occurs alongside a cluster pattern: 4 other insiders also purchased within the past 14 days, suggesting coordinated or aligned perspectives on valuation across leadership. The timing context is notable—the stock trades at $1.79 current price, down 22.2% over 30 days and down 53.3% from its 52-week high of $3.83. Nuvation Bio posted $3.1M revenue in its latest quarter against $-53.2M net income, indicating the company remains unprofitable and burning significant cash. The convergence of insider accumulation during a steep drawdown coincides with fundamental distress, warranting closer examination of management's investment thesis and the company's path to profitability.